About Dylan Sammut
Dylan joined Irving Levin in October 2018 as a Research and Editorial Associate and is responsible for reporting on mergers and acquisitions in the healthcare sector. He graduated from Alfred University in May 2014 with a degree in English and Political Science. He currently lives in Bridgeport, CT with his fiancé and his overweight cat, Kimba, and in his free time he plays video games, reads, writes, and hikes on the weekends all year around.
by Dylan Sammut | Mar 9, 2021 8:00 am | Biotechnology
The biotech giant Amgen, Inc. (NASDAQ: AMGN) has announced a new deal for Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. The company collaborates with leading global... Read More »
by Dylan Sammut | Mar 5, 2021 5:15 pm | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date... Read More »
by Dylan Sammut | Mar 1, 2021 3:53 pm | Healthcare Market Updates
The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date... Read More »
by Dylan Sammut | Mar 1, 2021 3:40 pm | Home Health & Hospice
After months of rumors swirling about a deal, Brookdale Senior Living (NYSE: BKD) has announced the divestment of a majority stake in its home health and hospice business, Brookdale Health Care Services. The senior living giant is selling an 80% interest in its home... Read More »
by Dylan Sammut | Mar 1, 2021 3:39 pm | CRO
The contract research organization giant ICON plc (NASDAQ: ICLR) is growing its market reach through the acquisition of PRA Health Sciences, Inc. (NASDAQ: PRAH). The deal is valued at $12 billion, with the per share merger consideration consisting of $80 in cash and... Read More »